Home About us Contact
|
Home About us Contact | ||
|
|
||
Hepatic Triglycerides (hepatic + triglyceride)
Selected AbstractsDecrease in stearic acid proportions in adipose tissues and liver lipids in fatty liver of dairy cowsANIMAL SCIENCE JOURNAL, Issue 3 2006Hiroshi SATO ABSTRACT Samples of liver and perirenal, mesenteric and subcutaneous fat were collected from 16 sick necropsied dairy cows to evaluate the fatty acid profiles in the hepatic and adipose tissues associated with advanced fatty liver or hepatic lipidosis. Hepatic triglyceride and eight fatty acids were measured in the hepatic and adipose tissues. Six cows had more than 3% triglyceride on fresh weight in their livers and were classified as having fatty liver. Stearic and linoleic acid proportions in the liver decreased markedly with increased hepatic triglyceride levels, while the proportion of palmitic and oleic acids increased. The most striking fluctuations in hepatic lipidosis were manifested as decreased stearic acid in the adipose tissues including subcutaneous fat with the trend of decreasing stearic acid. Palmitic acid was elevated in hepatic and perirenal fat in fatty liver cows. In instances of advanced hepatic lipidosis, palmitoleic acid increased in only subcutaneous fat and not in perirenal or mesenteric fat. In addition to the proportions of hepatic fatty acids in fatty liver, this study also clarified the fluctuations observed in the profiles of fatty acids of the adipose tissues in cows with advanced hepatic lipidosis, particularly the decline in the proportions of stearic acid. [source] Fucoxanthin-rich seaweed extract suppresses body weight gain and improves lipid metabolism in high-fat-fed C57BL/6J miceBIOTECHNOLOGY JOURNAL, Issue 9 2010Seon-Min Jeon Abstract An ethanol extract of fucoxanthin-rich seaweed was examined for its effectiveness as a nutraceutical for body fat-lowering agent and for an antiobese effect based on mode of actions in C57BL/6J mice. Animals were randomized to receive a semi-purified high-fat diet (20% dietary fat, 10% corn oil and 10% lard) supplemented with 0.2% conjugated linoleic acid (CLA) as the positive control, 1.43% or 5.72% fucoxanthin-rich seaweed ethanol extract (Fx-SEE), equivalent to 0.05% or 0.2% dietary fucoxanthin for six weeks. Results showed that supplementation with both doses of Fx-SEE significantly reduced body and abdominal white adipose tissue (WAT) weights, plasma and hepatic triglyceride (TG), and/or cholesterol concentrations compared to the high-fat control group. Activities of adipocytic fatty acid (FA) synthesis, hepatic FA and TG synthesis, and cholesterol,regulating enzyme were also lowered by Fx-SEE supplement. Concentrations of plasma high-density lipoprotein-cholesterol, fecal TG and cholesterol, as well as FA oxidation enzyme activity and UCP1 mRNA expression in epididymal WAT were significantly higher in the Fx-SEE groups than in the high-fat control group. CLA treatment reduced the body weight gain and plasma TG concentration. Overall, these results indicate that Fx-SEE affects the plasma and hepatic lipid profile, fecal lipids and body fat mass, and alters hepatic cholesterol metabolism, FA synthesis and lipid absorption. [source] Comparative study on hypocholesterolemic effect of Rhodopseudomonas palustris and Rhodobacter capsulatus on rats fed a high cholesterol dietANIMAL SCIENCE JOURNAL, Issue 5 2007Hirotada TSUJII ABSTRACT This comparative study was to investigate the hypocholesterolemic effects of dietary Rhodopseudomonas palustris and Rhodobacter capsulatus on rats fed a high cholesterol diet. Thirty male Wister,Imamichi rats were assigned to three groups and fed on either a high cholesterol diet, or a high cholesterol diet supplemented with 2.0% R. palustris or R. capsulatus for 4 weeks. Compared to the control diet, both of the R. palustris and R. capsulatus supplemented diets significantly reduced the serum cholesterol, triglycerides, low-density lipoprotein, very low density lipoprotein cholesterol and hepatic triglycerides, but increased hepatic cholesterol in rats. In addition, both of the R. palustris and R. capsulatus supplemented diets may reduce the risk of atherosclerosis, as the ratio of high density lipoprotein cholesterol to the total cholesterol was significantly higher than in the control group (P < 0.05). Both the R. palustris and R. capsulatus supplemented diets led to an increase in the serum palmitic acid, compared with the oleic acid and linoleic acid. No significant differences were postulated between the rats fed R. palustris and R. capsulatus supplemented diets during the 4 weeks of the experimental period. Thus, the results may suggest that both R. palustris and R. capsulatus can contribute significant health benefits and seems to be feasible to investigate in future research. [source] Hepatic Effects of Rosiglitazone in Rats with the Metabolic SyndromeBASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY, Issue 2 2010Zvi Ackerman In this study, we characterized the hepatic effects of rosiglitazone in fructose-enriched diet rats. Rats were randomly divided into three groups. One group was maintained on standard rat chow diet for 6 weeks, whereas the other two groups were given fructose-enriched diet for 6 weeks. Four weeks after the initiation of fructose-enriched diet, one of the fructose-enriched diet groups was also given rosiglitazone (10 mg/kg/day) for an additional 2 weeks. Rosiglitazone administration to the fructose-enriched diet rats was associated with decreases in the following parameters: blood pressure (,17%), plasma triglycerides (,62%), hepatic total lipids (,19%), hepatic triglycerides (,61%), hepatic malondialdehyde (,88%), glutathione reductase activity (,84%). An increase in adiponectin plasma levels (+329%), hepatic phospholipids (+46%), hepatic ,-tocopherol concentrations (+24%) and hepatic paraoxonase activity (+68%) was observed. Rosiglitazone caused a decrease in hepatic macrovesicular steatosis score but no change in hepatic fibrosis. Administration of rosiglitazone, to rats with the metabolic syndrome has limited hepatic favourable effects: it improves hepatic lipid metabolism, decreases macrovesicular steatosis and improves some of the hepatic oxidative,anti-oxidative milieu but has no effect on hepatic fibrosis. [source] | ||||||||||